CA-ARIBIO
AriBio USA, a clinical-stage biopharmaceutical company, announced the enrollment of their first participants in their Phase 3 trial to evaluate the efficacy of AR1001 in participants with early Alzheimer’s Disease (AD). AR1001 is a blood-brain barrier penetrating small molecule known to inhibit neuron apoptosis and promote neurogenesis, increase neuroplasticity and increase autophagy activity to remove toxic proteins.
This study is a randomized, placebo-controlled, double-blind, multi-center Phase 3 trial that plans to enroll 800 participants from approximately 75 sites for 12 months of treatment, followed by an optional two-year extension phase. Patients will be randomly assigned to receive either 30 mg of AR1001 or placebo once daily for 52 weeks. In the optional-extension study, participants originally assigned to placebo will receive 30 mg of AR1001 for an additional two years of treatment. The primary endpoint in the trial is the Change in the Clinical Dementia Rating Scale – Sum of Boxes (CDR-SB) at Week 52. “As we learn more about Alzheimer’s disease with the understanding that different therapeutic approaches are necessary to demonstrate a meaningful benefit to patients and their caregivers we look forward to data on AR1001,” said Dr. Greeley, CMO for AriBio USA.
“AriBio USA is excited to share this significant milestone, and we look forward to providing regular updates to the program as enrollment progresses in this Phase 3 trial. We continue to engage with interested investigators and sites who are committed to making a difference in the treatment and care of patients with Alzheimer’s disease,” said James Rock, CEO of AriBio USA, Inc. Enrollment is expected to require approximately 2 years for this Phase 3 trial. Dr. Greeley stated, “As we understand more about Alzheimer’s disease, with the understanding that different therapeutics and lifestyle approaches will be necessary to demonstrate a meaningful benefit to patients and their caregivers, we expect AR1001 to be part of this treatment paradigm.”
AriBio Ltd, the parent company of AriBio USA, is committed to developing new therapeutics in the neurology space with a pipeline of PDE-5 inhibitors and other new molecular entities. “Our goal is to transform the treatment options available for patients with dementia to improve their daily lives,” stated Dr. Matthew Choung, CEO of AriBio Ltd.
About AR1001-ADP3-US01
AR1001-ADP3-US01 (NCT05531526) is Phase 3 Double-blind, Randomized, Placebo-controlled, Multi-center Trial to Evaluate the Efficacy and Safety of AR1001 over 52 Weeks in Participants with Early Alzheimer’s Disease. The study aims to assess the efficacy and safety of AR1001 in slowing the progression of Alzheimer's disease through various cognitive and functional assessments. The details of the clinical trial are available at ClinicalTrials.gov.
About AriBio
AriBio Co., Ltd. is a biopharmaceutical company based in South Korea with a focus on the development of therapies for neurodegenerative diseases. AriBio USA, INC. is the subsidiary company of AriBio Co., Ltd. based in San Diego, CA in charge of clinical operations and regulatory affairs for AriBio.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230105005102/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AWS and HUMAIN Announce Groundbreaking AI Zone to Accelerate AI Adoption in Saudi Arabia and Globally13.5.2025 18:09:00 CEST | Press release
More than $5 billion joint investment in AI infrastructure, AWS services, and AI training and talent development will advance Saudi Arabia’s mission to be a global leader in AI Amazon Web Services, Inc. (AWS), an Amazon.com, Inc. company (NASDAQ: AMZN), and HUMAIN, Saudi Arabia’s newly created company responsible for driving AI innovation across the Kingdom and globally, today announced plans to invest $5 billion-plus in a strategic partnership to build a groundbreaking “AI Zone” in the Kingdom. This first-of-a-kind AI Zone will bring together multiple innovative capabilities, including dedicated AWS AI infrastructure and servers with world-class semiconductors, UltraCluster networks for faster AI training and inference, AWS services like SageMaker and Bedrock, and AI application services such as Amazon Q to advance Saudi Arabia’s mission to be a world leader in AI. AWS previously announced and is currently building an AWS infrastructure region in Saudi Arabia that will become availabl
Citco enters strategic partnership with GIC13.5.2025 17:05:00 CEST | Press release
The Citco group of companies (Citco) and GIC are pleased to announce that they have entered a long term, strategic relationship. As part of the relationship, GIC, a global institutional investor, has become a minority shareholder in Citco. The founding Smeets Family shall remain the majority shareholder in Citco. “Citco has organically grown into a global market-leading asset servicing business, delivering value to investors like GIC for over 50 years. Our investment aligns squarely with GIC’s commitment to building long-lasting partnerships that empower family-owned businesses to thrive. With a combination of client-centric solutions and savvy technological investments Citco is at the forefront of their industry. We look forward to partnering with Citco and the Smeets family as we embark on this new chapter together." – Girish Karira, Head of Integrated Strategies Group and Head, New York Office at GIC. “We look forward to continuing our strategic relationship with GIC. Their industry
Tigo Energy Resolves Multi-Year Patent Infringement Litigation With SMA13.5.2025 15:00:00 CEST | Press release
Settlement validates Tigo Intellectual Property, concludes IP litigation with SMA, and reinforces innovation in the marketplace. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy software solutions, today announced that it has reached a multi-year settlement with SMA (SMA Solar Technology AG and SMA Solar Technology America LLC) over litigation regarding the infringement of Tigo intellectual property by SMA. The settlement concludes the infringement complaint brought by Tigo on July 11, 2022, Case No. 1:22-cv-00915 (D. Del.) alleging infringement of certain patents by SMA. Terms of the settlement will remain undisclosed. According to National Electric Code § 690.12, “Rapid Shutdown of PV Systems on Buildings” requires that PV system circuits “installed on or in buildings shall include a rapid shutdown function to reduce shock hazard for emergency responders.” Tigo rapid shutdown technology is compliant with UL 1741, the Standard
GPs Rethink Operational Tactics Amid Rising SPV Complexity13.5.2025 15:00:00 CEST | Press release
Nearly three quarters of GPs cite growing regulatory burdens as a top risk LP demand accelerates shift to co-investment, sector-specific, and evergreen structures63% of GPs scale outsourcing to enhance efficiency and drive growth Faced with rising regulatory demands and operational pressures, general partners (GPs) are increasingly turning to outsourcing and technology to manage special purpose vehicles (SPVs) more efficiently. This trend is highlighted in a new report from CSC, the leading provider of global business administration and compliance solutions. CSC surveyed 400 GPs across the Americas, Europe (including the U.K.), and Asia Pacific to uncover how today’s market shifts and operational pressures are reshaping SPV management strategies.1 The full findings are detailed in the report SPV Global Outlook 2025: How GPs are Shaping Strategies for Long-Term Success. Regulatory compliance and risk mitigation are firmly at the top of GPs’ agendas, with nearly three-quarters identifyin
Boomi Announces FY25 EMEA Partner Award Winners13.5.2025 15:00:00 CEST | Press release
Boomi™, the leader in AI-driven automation, announced today the winners of its FY25 Europe, Middle East, and Africa (EMEA) Partner Awards - recognized at the 2025 Boomi Partner Summit held in Dallas, Texas. The awards recognize innovative partner organizations across the region that have harnessed the power of the Boomi Enterprise Platform to deliver outstanding customer outcomes, accelerate digital transformation, and build scalable, AI-ready data ecosystems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250513864198/en/ Boomi Announces FY25 EMEA Partner Award Winners Award winners were selected based on their ability to creatively solve complex business challenges, deliver measurable impact, and champion sustainable, forward-looking solutions for customers leveraging the Boomi platform’s end-to-end capabilities. “Across EMEA, organizations are under immense pressure to automate, integrate, and innovate — all while prepari
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom